Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding Ltd.    ROG   CH0012032048

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

FDA Approves Breast-Cancer Drug

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/22/2013 | 06:05pm CET

--Drug packs Roche's Herceptin with chemotherapy agent

--Drug approved for use as a first-line, or initial treatment for advanced breast cancer

WASHINGTON--The U.S. Food and Drug Administration Friday approved a powerful new type of drug that will be marketed by Roche Holding AG (ROG.VX, RHHBY) to treat breast cancer.

The drug called, Kadcyla, combines Roche's existing cancer drug, Herceptin, with a powerful chemotherapy agent, and is meant to treat certain types of breast cancer that have spread to other parts of the body.

Herceptin targets a protein called HER2 found on tumors in about 20% to 25% of breast-cancer patients. The two other components of Kadcyla, both developed by ImmunoGen Inc. (>> ImmunoGen, Inc.), are a chemotherapy agent called emtansine that is too potent to be delivered as a conventional medicine, and a linker that connects the two drugs. Herceptin then delivers the package to the tumor cell, where it releases the toxic cargo to kill the cancer.

The FDA's approval of Kadcyla, which was previously known as T-DM1, triggers a $10.5 million payment to ImmunoGen by Roche. ImmunoGen will also receive royalties on sales of up to 5%.

Analysts said the approval was broader than expected. The drug can be marketed for initial treatment rather than just in patients who've tried other therapies, creating a "significantly larger patient population," said Simos Simeondis, an analyst at Cowen and Company.

Roche's Genentech unit said Kadcyla will be available to patients in about two weeks. The drug will be priced at $9,800 a month. The company said there will be a patient-assistance program to help pay for the product.

Agents like Kadcyla are called antibody-drug conjugates and they are the focus of intense interest in the pharmaceutical industry. Roche's Genentech unit has 25 such agents under development for different cancers, including eight in human studies.

The first such agent to gain FDA approval was Seattle Genetics Inc.'s (>> Seattle Genetics, Inc.) Adcetris, for Hodgkin's Lymphoma and another rare cancer. That company and ImmunoGen are each collaborating with big pharmaceutical firms including Bayer AG (BAYRY, BAYN.XE), Eli Lilly & Co. (>> Eli Lilly & Co.), GlaxoSmith Kline PLC (GSK, GSK.LN), Pfizer Inc. (>> Pfizer Inc.), Sanofi (>> Sanofi SA) to develop several types of new cancer drugs.

The approval of Kadcyla was based on a study of about 1,000 women with HER2-positive breast cancer who had been treated previously with Herceptin and a traditional chemotherapy drug. About half of the women were then treated with T-DM1 and the other half were treated with a combination of Xeloda, another Roche drug, and GlaxoSmithKline's Tykerb. The study showed women receiving Kadcyla lived for an average of 31 months, which was about six months longer than women being treated with Xeloda and Tykerb.

However, like other cancer drugs Kadcyla has the potential to cause serious and life-threatening side effects from liver damage or heart problems. The drug can also cause severe birth defects so doctors need to make sure women of child-bearing age aren't pregnant before administering the product.

--Joseph Walker contributed to this story.

Write to Jennifer Corbett Dooren at jennifer.corbett@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ROCHE HOLDING LTD.
02/25 ROCHE : Behrend men fall to La Roche in AMCC semifinals Staff reports
02/24 ROCHE : Presolicitation Notice - 1 year service & support contract for two Roche..
02/23 ROCHE : European Commission conditionally approves Roches cancer drug Alecensa
02/23 ROCHE : You 'cannot hang on to' breast cancer drug, high court tells roche
02/22 FOUNDATION MEDICINE : reports 4Q loss
02/22 FOUNDATION MEDICINE, INC. : Results of Operations and Financial Condition, Finan..
02/22 ROCHE : TAC Calls for Roche to Drop Price of Cancer Drug
02/22 CHUGAI PHARMACEUTICAL : ALK Inhibitor 'Alecensa' Approved in the EUAlecensa is A..
02/22 ROCHE : Registration closing soon for 11th annual Paediatric Clinical Trials sho..
02/21 ROCHE : Enters Hematology Market with Integrated Analyzer
More news
Sector news : Pharmaceuticals - NEC
02/24DJSHIRE : Files 8K - Other Events
02/24DJASTRAZENECA : Hyperkalaemia Drug Clears Scientific Hurdle for European Approval
02/24DJASTRAZENECA : Gets Approval for Drug Treating Hyperkalaemia
02/24 Exclusive - Trump says Republican border tax could boost U.S. jobs
02/23DJPFIZER : Files 8K - Changes Executive Management
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
02/24 Truxima Fires The Starting Gun In Biosimilar Race To The Bottom
02/24 The Risks Keep Rising For Roche's Hemophilia Hope
02/24 SYNERGY : 3 Scenarios, 1 Choice
02/22 Should Merck, BMS Fear Roche's Drug Becoming The I-O King?
02/21 PROTALIX BIOTHERAPEUTICS : New Institutional Ownership Swells Ahead Of Major Cat..
Advertisement
Financials ( CHF)
Sales 2017 53 280 M
EBIT 2017 18 459 M
Net income 2017 11 591 M
Debt 2017 8 928 M
Yield 2017 3,52%
P/E ratio 2017 18,08
P/E ratio 2018 16,76
EV / Sales 2017 4,15x
EV / Sales 2018 3,84x
Capitalization 212 251 M
More Financials
Chart ROCHE HOLDING LTD.
Duration : Period :
Roche Holding Ltd. Technical Analysis Chart | ROG | CH0012032048 | 4-Traders
Full-screen chart
Technical analysis trends ROCHE HOLDING LTD.
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 279  CHF
Spread / Average Target 14%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
John Irving Bell Non-Executive Director
Andreas Oeri Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING LTD.5.98%210 192
JOHNSON & JOHNSON5.63%333 891
PFIZER INC.4.86%207 902
NOVARTIS AG4.72%202 648
MERCK & CO., INC.11.86%182 412
SANOFI4.38%109 848
More Results